TMPRSS2:ERG gene fusions and PTEN deletions are the most common genomic aberrations in prostate cancer. Recent work has suggested that the TMPRSS2:ERG fusion is associated with a more aggressive phenotype. Similarly, PTEN deletion has been associated with biochemical recurrence and lymph node metastasis. To date, there has been no systematic analysis of the combined influence of genomic PTEN deletion with TMPRSS2:ERG gene fusions on clinical parameters of prostate cancer progression. We carried out a retrospective analysis of 125 prostate cancers with known clinical outcome using interphase fluorescence in situ hybridization to detect the relative prevalence of TMPRSS2:ERG rearrangements and/or PTEN genomic deletions. TMPRSS2:ERG rearrangement was found in 60 of 125 (48%) prostate cancers. Duplication of TMPRSS2:ERG fusion was observed in seven (6%) tumors. Gleason grade (P ¼ 0.0002)/score (P ¼ 0.001), median tumor volume (P ¼ 0.0024), preoperative PSA (P ¼ 0.001) and perineural invasion (P ¼ 0.0304) were significantly associated with biochemical recurrence by univariate analysis with TMPRSS2:ERG approaching significance (P ¼ 0.0523). By multivariate analysis, relevant factors associated with recurrence were Gleason scores 7 (P ¼ 0.001) and 8-10 (P ¼ 0.015), PTEN homozygous deletion (P ¼ 0.013) and concurrent TMPRSS2:ERG fusion and PTEN deletion (P ¼ 0.036). Kaplan-Meier analysis indicated that the presence of TMPRSS2:ERG fusion was marginally less favorable in comparison to no fusion. Duplication of fusion gene showed worse prognosis. It was possible to determine the relative frequencies of PTEN deletion and/or TMPRSS2:ERG fusions in 82 of 125 prostate cancers. With biochemical recurrence as an endpoint, the genomic biomarkers identified three patient groups: (1) 'poor genomic grade' characterized by both PTEN deletion and TMPRSS2:ERG fusions (23/82, 28%); (2) 'intermediate genomic grade' with either PTEN deletion or TMPRSS2:ERG fusion (35/82, 43%) and (3) 'favorable genomic grade' in which neither rearrangement was present (24/82, 29%). Kaplan-Meier and multivariate analysis indicate that TMPRSS2:ERG fusion and PTEN loss together are a predictor of earlier biochemical recurrence of disease.
The identification of prognostic molecular biomarkers is recognized as critically important in the future clinical management of prostate cancer. Despite the clinical utility of Gleason score, pathological stage and serum PSA in assessing prognosis and guiding management, further molecular determinants are needed that more accurately address pathways that underlie tumorigenesis of prostate cancer. 1 Chromosomal deletions of 10q suggested that the phosphatase and tensin homologue (PTEN) gene at cytoband 10q23.3 is strongly associated with the progression of prostate cancer. [2] [3] [4] PTEN plays an important role in the modulation of the phosphatidylinositol-3-kinase (PI3K) pathway by catalyzing degradation of phosphatidylinositol-(3,4,5)-triphosphate (PIP3) generated by PI3K. 5 PIP3 activates the protein kinase AKT which then modulates a number of downstream targets with important roles in apoptosis and the cell-cycle progression, including BAD, 6 CASP3 and CASP9, 7 MDM2, 8 mTOR, 9 FKHR 10 and FOXO3A, 11 p27 12 and the recently recognized JNK pathway. 13 PTEN deletion is associated with tumor progression [14] [15] [16] and more predictive of shorter time to biochemical recurrence of disease, 17 emphasizing the crucial role of PTEN as marker of tumor behavior in prostate cancer.
The discovery of recurrent translocations in B40-60% of prostate carcinoma, 4, [18] [19] [20] [21] [22] [23] [24] involving the TMPRSS2 gene at 21q22.3 with members of the erythroblast transformation specific (ETS) transcription factor family, such as ERG (21q22.2), ETV1 (7p21.2), ETV4 (17q21) or ETV5 (3q28) genes, has provided new insights into prostatic carcinogenesis. Although the downstream molecular pathways of ETS fusion genes are only beginning to be clarified, clinical associations have been reported in early studies. 19, 22, [25] [26] [27] [28] For instance, TMPRSS2:ERG-rearranged prostate cancers have been associated with a greater likelihood of lethal prostate cancer, 26, 27 moderate to poorly differentiated tumors 25 and higher stage diseases with pelvic lymph node metastases. 19 Evidence of specific TMPRSS2:ERG isoforms were also described to be associated with high levels of fusion mRNA expression and early biochemical recurrence following radical prostatectomy. 22 However, there are a number of conflicting studies 29, 30 about the prognostic importance of the gene fusion; so the clinical significance of TMPRSS2:ERG fusions remains to be clarified.
Given the potential of both TMPRSS2:ERG fusions and PTEN genomic deletions to contribute to prognosis prediction in prostate cancer, additional genotype-phenotype correlation studies will be helpful. In addition, it is unclear whether the TMPRSS2:ERG rearrangements may be accompanied by PTEN genomic loss, or in contrast, these are mutually exclusive events. There has been no systematic analysis to date of the frequency at which PTEN and TMPRSS2:ERG rearrangements occur simultaneously in prostate cancer, or to examine clinical phenotypes associated with genomic mutations affecting both pathways. Therefore, this study was designed to retrospectively assess the overall frequency and clinical impact of TMPRSS2:ERG rearrangements using a clinicallyannotated tissue microarray. We also provide the results of clinical impact of cooperation between TMPRSS2:ERG gene rearrangements and PTEN genomic deletion in prostate cancer samples that became available after the publication of our previous study. 17 Our results further implicate TMPRSS2:ERG rearrangements as a prognostic value in the primary tumor, in addition to providing insights into prostate cancer pathophysiology.
Materials and methods

Tissue Specimens
The collection of all tissue specimens, clinical and patient follow-up data was obtained after informed consent in accordance with the Hospital do Câncer Research Ethics guidelines (São Paulo, Brazil). Archival formalin-fixed, paraffin-embedded tissues were obtained from 125 radical prostatectomies performed between 1997 and 2000 at the Hospital do Câncer, AC Camargo, São Paulo, Brazil. For control purposes, 10 non-neoplastic prostate tissue samples were obtained from patients undergoing surgery solely for benign prostate hyperplasia. The prostate cancer cohort and control specimens were sampled using a 0.6-mm diameter tissue core distributed on tissue microarray slide. Adjacent hematoxylin and eosin (H&E) stained section was reviewed by two pathologists to determine the presence and extent of morphologically representative areas of the original tumors in each tissue core. Reassessment of Gleason grading in a contiguous H&E stained tissue microarray section assured the presence of prostate adenocarcinoma and the fidelity of the intended tissue microarray core. The size of tumor was based on assessment of total surface area of gland examined histologically involved by carcinoma. Preoperative PSA level was available for all patients and the PSA nonfailure was defined as PSA remaining below 0.2 ng/ml after radical prostatectomy.
Fluorescence In Situ Hybridization
Break-apart fluorescence in situ hybridization (FISH) was used for studying the TMPRSS2:ERG gene rearrangement as previously described. 31 The following bacterial artificial chromosome (BAC) clones were used. BACs located at: (a) the 3 0 ERG gene locus (RP11-476D17, 3
0 ERG sequence extending inward past exon 4), (b) the 5 0 ERG gene locus (RP11-95I21, 5 0 ERG sequence extending inward into exon 10), (c) the TMPRSS2 locus (RP11-535H11) and (d) the telomeric BACs to the 5 0 end of TMPRSS2 locus (RP11-35C4, RP11-891L10 and RP11-260O11, 325 kb downstream from the 5 0 end of the TMPRSS2 gene; Figure 1a ). The BAC clones were obtained from The Center for Applied Genomics (Toronto, Canada). DNA was extracted and labeled with SpectrumGreen-dUTP, SpectrumOrange-dUTP (Vysis Inc., Downers Grove, IL, USA) or diethylaminocoumarin (DEAC)-dUTP (PerkinElmer Life and Analytical Sciences, Boston, MA, USA) using the Vysis nick-translation kit according to manufacturer's instructions (Vysis Inc.). The integrity and correct chromosome localization of all BAC clones were verified by hybridization to metaphase spreads of normal peripheral lymphocytes.
Sequential dual-color FISH method was applied to the prostate cancer tissue microarray to investigate the occurrence of PTEN genomic deletion in addition to TMPRSS2:ERG gene rearrangements in 82 of 125 prostate cancer cohort. Dual-color FISH on paraffin-embedded tissue microarray tissue was performed using commercially available DNA probes for cytoband 10q23 (Spectrum Orange PTEN locus-specific probe) and region 10p11.1-q11.1 (Spectrum Green centromere of chromosome 10 probe) (LSI PTEN/CEP 10; Vysis Inc.). The PTEN genomic probe spans 368 kb and starts 166 kb from 5 0 end of the gene and extends 98 kb past the 3 0 end of the gene (Figure 1b) . Histologic tissue microarray tissue sections (5 mm) were deparaffinized with a series of xylene prior to immersion in 100% ethanol. FISH was carried out as described. 17 
Data Analysis
The TMPRSS2:ERG fusion was evaluated for each probe by spot visualization and enumeration in a range from 50 to 100 nonoverlapped, intact interphase nuclei per tumor tissue core using a Zeiss Imager.Z1 microscope equipped with a digital camera AxioCam MRm and AxioVision 4. 0 end of TMPRSS2 (blue signal) was well separated from the 3 0 ERG BAC (red signal), the TMPRSS2:ERG rearrangement was confirmed using the TMPRSS2 BAC (RP11-535H11-blue), 5 0 ERG (RP11-95I21-green) and 3 0 ERG BAC (RP11-476D17-red). Based on hybridization in 10 control cores (data not shown) and tumor cohort, the detection of TMPRSS2:ERG rearrangement was defined as cutoff 410% when the distance between signals was 43 times the estimated signal diameter.
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PTEN copy number was evaluated for each probe by counting spots in a range from 50 to 100 nonoverlapped, intact interphase nuclei per tumor tissue core. Based on hybridization in 10 control cores (data not shown), hemizygous deletion of PTEN were defined as 420% (mean þ 3 s.d. in nonneoplastic controls) of tumor nuclei containing one PTEN locus signal and by the presence of CEP 10 signals. Homozygous deletion of PTEN was exhibited by the simultaneous lack of the both PTEN locus signals and by the presence of control signals [32] [33] [34] [35] in 430% of cells. 33 
Statistical Analysis
FISH findings for TMPRSS2:ERG fusion were correlated in a univariate and multivariate fashion with clinical and pathologic measures of disease aggressiveness. A comprehensive description of the clinical parameters associated with the adenocarcinomas having the TMPRSS2:ERG fusion is summarized in Table 1 . Frequency of TMPRSS2:ERG rearrangements was also correlated with PTEN genomic deletion in addition to determinants of disease mortality and morbidity, such as PSA, and extraprostatic extension and time to biochemical relapse. Univariate and multivariate analyses of risk of biochemical failure were studied by Cox proportional hazard model. A significant correlation between two parameters was taken at the 95% confidence interval. P-values o0.05 were considered significant. The survival rate was estimated by applying the Kaplan-Meier method. The endpoint for calculating the survival time was defined by time from radical prostatectomy until the occurrence of metastasis or PSA determined biochemical recurrence, ie the date of first PSA increase above 0.2 ng/ ml. (median follow-up time 87.4 months, range 11.5-161.6). All calculations were performed using Stata 9.1 (StataCorp LP).
Results
TMPRSS2:ERG Fusion
A total of 125 archival tissues with anonymous clinical annotation were analyzed for TMPRSS2:ERG rearrangements by interphase tricolor FISH. TMPRSS2:ERG rearrangement was found in 60 of 125 (48%) prostatic adenocarcinomas samples. There was evidence of TMPRSS2:ERG fusion with deletion of 5 0 ERG probe in 43 of 125 (34%) cases. As previously characterized, 31 sequential FISH analysis using the BAC set telomeric to the 5 0 end of TMPRSS2 (RP11-35C4, RP11-891L10 and (Table 2 ). There was evidence of FISH The three atypical cases were excluded from the clinicopathological correlation analysis given that complex genomic rearrangement involving an unknown chromosomal partner(s) could not be elucidated as previously described. Median overall survival was 87.4 months (11.5-161.6).
Values in parentheses indicate the percentage of sample in each category. P-value ¼ w 2 -analysis.
TMPRSS2:ERG fusion with no deletion of 5 0 ERG probe in 17 of 125 (14%) cases. Only 1 of the 17 cases showed the BAC set telomeric to the 5 0 end of TMPRSS2 (RP11-35C4, RP11-891L10 and RP11-260O11-blue) well separated from the 3 0 ERG BAC (RP11-476D17-red) ( Table 2 ).
In addition to the 60 TMPRSS2:ERG fused cases, 3 atypical cases had abnormal TMPRSS2:ERG FISH colocalization pattern. The 3 0 ERG RP11-476D17 (red signal) did remain juxtaposed to the 5 0 ERG RP11-95I21 (green signal), but failed to exhibit the expected colocalization of the TMPRSS2 locus (RP11-535H11-blue) with the ERG gene probes. We were not able to detect FISH fusions between TMPRSS2 and ETV1 or ETV4 in any of these three cases with abnormal FISH TMPRSS2:ERG breakapart results. Furthermore, extra copies of the TMPRSS2 locus (RP11-535H11-blue) were observed in the atypical samples. Such findings indicate that: (a) fusion events between TMPRSS2 and other genes are possible and (b) TMPRSS2:ERG fusions may sometimes have concurrent complex genomic rearrangements within the B2.9 Mb that separates these two genes. However, the three atypical cases were excluded from the clinicopathological correlation analysis given that complex genomic rearrangement involving an unknown chromosomal partner(s) could not be elucidated.
Among the 60 rearranged TMPRSS2:ERG tumors detected, the Gleason scores were 4-6 (35 tumors), 7 (17 tumors) and 8-9 (8 tumors). A median tumor volume of 420% was found in 25/60 rearranged TMPRSS2:ERG tumors. In addition, early biochemical recurrence was detected in all seven samples with an extra copy of TMPRSS2:ERG fusion associated with deletion of 5 0 ERG probe.
Concomitant Presence of TMPRSS2:ERG Fusion and PTEN Genomic Deletion
After acquisition of FISH data, the cases were reviewed to search for potential associations between PTEN deletion as studied previously, 17 and TMPRSS2:ERG rearrangements. Therefore, we examined differential status of PTEN (deleted or not deleted) and presence of TMPRSS2:ERG fusion in 82 of the 125 tumor samples to assess its utility as biomarker of prognosis. Overall, PTEN deletion in addition to the presence of TMPRSS2:ERG rearrangement was observed in 23 of 82 (28%) prostatic adenocarcinomas. PTEN deletion was also found in 14 prostate adenocarcinoma samples showing absence of TMPRSS2:ERG rearrangement (14/82, 17%). There was evidence of no copy change of PTEN locus with TMPRSS2:ERG fusion in 21 of 82 (26%) cases and no copy change of PTEN locus with absence of TMPRSS2:ERG fusion in 24 of 82 (29%) cases. The description of the TMPRSS2:ERG fusion concomitantly with PTEN deletion is summarized in Table 3 . A comprehensive description of the clinicopathological parameters associated with 47 adenocarcinomas (23 cases showing both PTEN deletion and TMPRSS2:ERG fusion, and 24 cases in which neither rearrangement was present) is summarized in Table 4 . Representative images of TMPRSS2:ERG rearrangement and PTEN deletion are shown in Figure 2 .
Statistical Analysis of Clinical Parameters and Genomic Alterations
High Gleason score and clinical parameters of aggressive disease such as extraprostatic extension (P ¼ 0.0002), seminal vesicle invasion (P ¼ 0.0023), margin status (P ¼ 0.0008), neoadjuvant hormone therapy (P ¼ 0.0004), Gleason grade (P ¼ 0.0002)/ score (P ¼ 0.001), median tumor volume (P ¼ 0.0024), preoperative PSA (P ¼ 0.001), PTEN deletion (P ¼ 0.009), concurrent TMPRSS2:ERG fusion and PTEN deletion (0.001) and perineural invasion (P ¼ 0.0304) were significantly associated with biochemical recurrence by univariate analysis with TMPRSS2:ERG approaching significance (P ¼ 0.0523; Table 5 ). By multivariate analysis, relevant factors to explain biochemical failure included Gleason score (7 and 8-10, P ¼ 0.001 and P ¼ 0.015, respectively), concurrent TMPRSS2:ERG fusion and PTEN deletion (0.036) and PTEN homozygous deletion (0.013). The PTEN findings reflect those previously reported for this cohort 17 (Table 6 ). For comparison purpose, Kaplan-Meier survival analysis applying established clinical markers, such as the preoperative PSA, seminal vesicle invasion and surgical margins status, was considered to identify subgroups with different prognosis with respect to time to relapse after surgery. The estimated disease-free survival curves demonstrated association between TMPRSS2:ERG fusion and short time based on PSA recurrence intervals (Figure 3a) . Significantly, the occurrence of duplication of the TMPRSS2:ERG fusion was associated with a much earlier onset of biochemical recurrence based on PSA values (Figure 3b) . Furthermore, the estimated disease-free survival curves demonstrated considerable association of coexisting PTEN deletion and TMPRSS2:ERG rearrangements with short time based on PSA recurrence intervals (Figure 3c ). This analysis allowed for three broad groupings of differential patient outcome based on time to biochemical recurrence: (1) a poor prognostic group characterized by both PTEN deletion and TMPRSS2:ERG fusions; (2) an intermediate group with either PTEN deletion or TMPRSS2:ERG fusion and (3) a favorable prognostic group with neither event.
Discussion
The search for accurate biomarkers in prostate cancer is critical for evolution of accurate management of prostate cancer. This study evaluated the two leading genomic biomarkers (PTEN deletion and TMPRSS2:ERG rearrangements) for their contribution to prostate cancer prognosis in a large Brazilian cohort. Figure 3c illustrates the two 19, 22 whereas subsets with earlier stage disease tend to have lower incidence. 26, 27 This association of the gene rearrangement with more advanced disease has been suggested previously. 36 Indeed several large cohorts have suggested an adverse prognostic impact of the ETS fusion genes with both pathological 19, 28 and overall survival endpoints. 26, 27 The confirmation of the finding of poorest prognosis associated with the duplication of gene fusion via 5 0 ERG deletion variant also likely highlight important aspects of the pathophysiology of prostate cancer. The effective double dose of ERG gene alteration associated with this variant is likely to lead to an increased rate of biochemical recurrence seen in our and other cohorts. 26, 37, 38 Collectively, our data indicates that the duplication of gene fusion via 5 0 ERG deletion variant is predictive of a shorter time to biochemical recurrence of disease. However, some authors have suggested that duplication of the fusion may be a manifestation of general polyploidy rather than a specific duplication event. 39 As PTEN deletion and TMPRSS2:ERG abnormalities could be additive or mutually exclusive, we evaluated the prognostic information gained by TMPRSS2:ERG analysis alone and in combination with genomic PTEN deletions. The additive effect seen may relate to increased cellular motility, a phenotype that can be attributable to both ETS fusion 40 and PTEN deletion. 41, 42 Thus together, activation of these pathways may facilitate epithelial-mesenchymal transition that is characteristic of malignant transformation. 43 To further explore the potential for synergy between these genomic events, we used Oncomine 44 to interrogate two publicly available microarray studies of prostate cancer progression for differentially expressed genes between ETS overexpressing and nonoverexpressing prostate cancers. 45, 46 The ETS overexpressing prostate cancers demonstrated dysregulation of genes particularly involved in the Wnt pathway. PTEN deletion and its sequel are also likely to affect the same pathways and synergize with the consequences of ETS-related overexpression. Akt activation is also known to inhibit 
GSK3b
. 3, 47 The combination of these two events would theoretically lead to extra translocation of b-catenin to the nucleus further assisting cellular motility and epithelial to mesenchymal transition. 48 Additionally, we observed an upregulation of BRAF in ETS overexpressing tumors, such that combined signaling through ERK is also likely to increase cellular migration phenomena.
Our new findings suggests that the subgroup with absence of both TMPRS2:ERG and genomic PTEN alterations may be designated as favorable genomic grade. Kaplan-Meier and multivariate analysis indicates that TMPRSS2:ERG fusion and PTEN loss together are a predictor of earlier biochemical recurrence of disease. The acquisition of the TMPRSS2:ERG fusion and concomitant PTEN deletion at an earlier phase in prostatic oncogenesis appear to be an additional determinant of the phenotype that govern a more aggressive tumor phenotype. Further studies should validate this 
